# US 2008/0076134 A1 · Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0076134 A1
- Document ID: US20080076134A1
- Status: Published application
- Kind: A1
- Application number: 11/903,470
- Filed: 2007-09-21
- Published: 2008-03-27
- Earliest claimed: 2006-09-21
- Assignees: Nuclea Biomarkers, LLC
- Inventors: Patrick Muraca
- Web page: https://patentgrep.com/patent/US20080076134A1

## CPC

- G01N 33/6803: {General methods of protein analysis not limited to specific proteins or families of proteins}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/158: Expression markers
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention includes gene and protein expression profiles indicative of whether a cancer patient is likely to respond to treatment with irinotecan. By identifying such responsiveness, a treatment provider may determine in advance those patients who would benefit from such treatment, as well as identify alternative therapies for non-responders. The present invention further provide methods of using the gene and/or protein expression profiles and assays for identifying the presence of a gene and/or protein expression profile in a patient sample.

## Claims

### Claim 1

A gene expression profile for determining if a patient is a responder to treatment with irinotecan comprising at least about four or more genes selected from the group consisting of: ERBB2, GRB7, Erk1 kinase, JNK1 kinase, BCL2, MK167, phospho-Akt, CD68, BAG1, phospho-GSK-3beta, MMP11, CTSL2, CCNB1, BIRC5, STK6, MRP14 and GSTM1.

### Claim 2 (depends on 1)

The gene expression profile of claim 1 further comprising at least one reference gene.

### Claim 3 (depends on 2)

The gene expression profile of claim 2 wherein the reference gene is selected from the group consisting of: ACTB, GAPD, GUSB, RPLP0 and TFRC.

### Claim 4

A method of determining if a patient is a responder to treatment with irinotecan comprising:
a. obtaining colon cancer tissue from at least one patient diagnosed with colon cancer; and
b. determining the presence or absence in the sample of a gene expression profile wherein at least about four or more genes selected from the group consisting of: ERBB2, GRB7, JNK1 kinase, BCL2, MK167, phospho-Akt, CD68 and BAG1, are up-regulated and Erk1 kinase, phospho-GSK-3beta, MMP11, CTSL2, CCNB1, BIRC5, STK6, MRP14 and GSTM1 are down-regulated.

### Claim 5 (depends on 1)

The method of claim 1 further comprising at least one reference gene.

### Claim 6 (depends on 5)

The method of claim 5 wherein the reference gene is selected from the group consisting of: ACTB, GAPD, GUSB, RPLP0 and TFRC.

### Claim 7

A method of determining if a patient is a responder to treatment with irinotecan comprising:
a. obtaining colon cancer tissue from at least one patient diagnosed with colon cancer; and
b. determining the presence or absence in the sample of a protein expression profile wherein at least about four or more proteins selected from the group consisting of: ERBB2, GRB7, JNK1 kinase, BCL2, MK167, phospho-Akt, CD68 and BAG1, are up-regulated and Erk1 kinase, phospho-GSK-3beta, MMP11, CTSL2, CCNB1, BIRC5, STK6, MRP14 and GSTM1 are down-regulated.

### Claim 8 (depends on 1)

The method of claim 1 further comprising at least one reference protein.

### Claim 9 (depends on 5)

The method of claim 5 wherein the reference protein is selected from the group consisting of: ACTB, GAPD, GUSB, RPLP0 and TFRC.

### Claim 10 (depends on 7)

The method of claim 7 wherein step (b) is performed using immunohistochemistry.
